Introducing Luna Diabetes: Our Journey and a Pivotal Milestone

For as long as I can remember, managing diabetes has been an ever-present part of my life. Since being diagnosed with Type 1 diabetes at the age of four, I've lived through every imaginable challenge, sleepless nights, and constant worry about keeping my glucose levels in check. In the early years, my diabetes was managed through twice daily bovine insulin injections and urine glucose testing, then came more rapid blood glucose testing, then insulin pens, then better analog insulins, smart insulin pens, CGM and then - holy smokes - starting to close the loop thanks to the incredible work of Dana Lewis. I had seen the holy grail as I sat alone at night in my apartment in Stockholm, building this first automated insulin delivery system at night when my twin boys (occasionally) slept at night ten years ago. <img src="/assets/blog/introducing-luna-diabetes/js-dyi-diabetes.png" alt="A do-it-yourself closed-loop rig laid out on a blue background: an insulin pump, a single-board computer with a radio bridge, a battery pack and a small display, wired together" width="400" height="251" loading="lazy" decoding="async" /> That personal experience of waking up every morning with my blood sugar in range—almost totally removing CGM alarms and alerts from my life—not having to wake up to go to the bathroom—was life-changing for me and my family—and this is what inspired the founding of Luna Diabetes and joining forces with Jon Brilliant and Sean Saint.

At Luna, we believe in creating a more straightforward, safer, and more balanced approach to diabetes care, especially regarding nighttime glucose control. Our goal is to make the most advanced technologies, with significant clinical benefits, much more accessible to drastically more people. I believe we are achieving this goal in the most significant way ever in our careers with Luna. For us, it’s about making diabetes less complex and less costly so we can focus on everything other than diabetes more of the time.

More than 90% of US adults who use insulin take it by injection rather than with a pump, according to a Luna calculation from dQ&A’s segment-sizing assumptions.¹²³ Did you know that despite how amazing insulin pumps are for some people, the overwhelming majority of people living with diabetes are unwilling or unable to use one?

German/Austrian registry data for adults with type 1 diabetes on multiple daily injections and intermittently scanned CGM reported an adjusted mean of 40% of the night above 180 mg/dL (11pm–6am; n=95). In a separate study that tracked 25 adults with type 1 diabetes, 77% of 243 nights were poor-quality sleep, measured by wrist actigraphy. Luna is the world’s smallest patch pump. It offers the simplest onboarding experience of any AID system and the first algorithm designed for use with insulin pens.

Today, I’m thrilled to announce a significant step forward in that mission: the start of our Pivotal Trial for Luna’s first product, a groundbreaking therapy designed to help people with insulin-requiring diabetes who are unwilling to wear a traditional insulin pump to experience the wonder of automated insulin delivery.

Why Luna?

Luna was born out of necessity. For years, we knew the difficulties of nighttime glucose management firsthand. With Luna, we set out to design a product for the night: one that works alongside the insulin pens and CGM people already use, while they sleep. It's a product that works harmoniously with your insulin pens and continuous glucose monitors, providing peace of mind during the hours you need it most.

Our Pivotal Trial: What It Means

Starting this trial is a significant milestone for us, bringing us closer to offering Luna to the millions of people who could benefit from it. The trial will evaluate the safety and effectiveness of our system, and it’s a significant step toward regulatory approval. The trial will evaluate Luna's safety and effectiveness, and we look forward to sharing the results when they are available.

If you’re interested in our clinical studies, get in touch and we will email you with more information.

Sources

1. dQ&A, PWD Survey Results: Luna Patient Segmentation & Jobs To Be Done, January 2026 (fieldwork 13–19 December 2025), slide 63. Segment-sizing assumptions, not survey-measured: 9,406,000 injection users of 10,300,000 US adult insulin users (91.3%); includes 6.0 million basal-only users counted as injection users.

2. Sandig D, Grimsmann J, Reinauer C, et al. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry. Diabetes Technol Ther. 2020;22(8):602–612. doi:10.1089/dia.2020.0019. Table 4: adults with type 1 diabetes on multiple daily injections and intermittently scanned CGM, n=95; 11pm–6am, adjusted mean.

3. Botella-Serrano M, Velasco JM, Sánchez-Sánchez A, Garnica O, Hidalgo JI. Evaluating the influence of sleep quality and quantity on glycemic control in adults with type 1 diabetes. Front Endocrinol. 2023;14:998881. doi:10.3389/fendo.2023.998881. Wrist actigraphy: 243 nights in 25 adults.